ArticleBMC oral health2026
The progression of proliferative verrucous leukoplakia can be detected through elevated levels of salivary matrix metalloproteinases.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe management of follow-up in proliferative verrucous leukoplakia (PVL) cases remains highly challenging due to the absence of established etiological factors and limited understanding of disease progression. The aim of this study was to identify optimal biomarkers of PVL behavior to facilitate decision-making in complex therapeutic management.
methodsSalivary levels of matrix metalloproteinases (MMPs) were evaluated in 54 confirmed PVL cases. All patients underwent follow-up at Oral Medicine Department, Dentistry Clinic at University Hospital Pilsen. Unstimulated saliva samples were collected and analyzed for MMP-1, -2, -3, -7, and − 9 concentrations. Criteria for PVL stability and progression were defined. Disease progression in individual cases was retrospectively correlated with salivary MMP levels to identify optimal prognostic markers.
resultsAssessment of PVL progression and stability was performed 6 months after salivary MMP sampling. Progression was observed in 63% of patients (34/54). Significant associations between elevated salivary MMP levels and PVL progression were confirmed for four of the five MMPs tested. MMP-1, -3, -7, and − 9 emerged as promising markers. A combination of MMP-3 and MMP-7 demonstrated the best prognostic performance, with a sensitivity of approximately 79.5% and a specificity of 89%.
conclusionsThis is the first study to evaluate salivary MMPs for PVL monitoring. Our findings confirm an association between elevated salivary MMP levels and an increased risk of PVL progression. This non-invasive approach may improve clinical management and follow-up of patients with PVL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.